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Objectives This study sought to ascertain the relationship of 9p21 locus with: 1) angiographic coronary artery disease (CAD)
burden; and 2) myocardial infarction (MI) in individuals with underlying CAD.
Background Chromosome 9p21 variants have been robustly associated with coronary heart disease, but questions remain on the
mechanism of risk, specifically whether the locus contributes to coronary atheroma burden or plaque instability.
Methods We established a collaboration of 21 studies consisting of 33,673 subjects with information on both CAD (clini-
cal or angiographic) and MI status along with 9p21 genotype. Tabular data are provided for each cohort on the
presence and burden of angiographic CAD, MI cases with underlying CAD, and the diabetic status of all subjects.
Results We first confirmed an association between 9p21 and CAD with angiographically defined cases and control sub-
jects (pooled odds ratio [OR]: 1.31, 95% confidence interval [CI]: 1.20 to 1.43). Among subjects with angio-
graphic CAD (n  20,987), random-effects model identified an association with multivessel CAD, compared with
those with single-vessel disease (OR: 1.10, 95% CI: 1.04 to 1.17)/copy of risk allele). Genotypic models showed
an OR of 1.15, 95% CI: 1.04 to 1.26 for heterozygous carrier and OR: 1.23, 95% CI: 1.08 to 1.39 for homozy-
gous carrier. Finally, there was no significant association between 9p21 and prevalent MI when both cases
(n  17,791) and control subjects (n  15,882) had underlying CAD (OR: 0.99, 95% CI: 0.95 to 1.03)/risk allele.
Conclusions The 9p21 locus shows convincing association with greater burden of CAD but not with MI in the presence of un-
derlying CAD. This adds further weight to the hypothesis that 9p21 locus primarily mediates an atherosclerotic
phenotype. (J Am Coll Cardiol 2013;61:957–70) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.10.051
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9p21 and Angiographic CAD March 5, 2013:957–70Genome-wide association studies (GWAS) first identified
the 9p21 locus as associating with coronary heart disease
(CHD) in 2007 (1–3). A plethora of replication studies have
since confirmed and validated this association in a series of
different ethnic populations, making this the most robust
genetic finding for CHD to date. The need for large study
samples in many of these studies has led to phenotypic
heterogeneity with inclusion of cases with acute or stable
clinical presentations with presumed healthy control popu-
lations and varying definitions of CHD, including clinical or
noninvasive diagnosis of coronary artery disease (CAD),
angiographic CAD, validated myocardial infarction (MI),
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clarity has resulted in uncertainty about the primary
phenotype mediated by the 9p21 locus, specifically
whether it predisposes to atherosclerosis or promotes a
more abrupt plaque rupture or thrombotic process lead-
ing to MI. This in turn has hampered contextualization
of early functional studies attempting to resolve the
underlying mechanism (6).
There have been several attempts to tease apart the closely
related phenotypes of CAD and MI (7–9). In the most
comprehensive analysis to date, Reilly et al. (8) demon-
strated that, although 11 variants had shown robust associ-
ation with MI in GWAS when compared with healthy
control subjects, they did not associate with MI when both
cases and control subjects had underlying CAD. It was thus
proposed that the primary association for these variants
was likely to be with development of CAD rather than
predisposition to plaque rupture or thrombosis per se. It
follows then that carriers of the risk allele at the 9p21
locus should demonstrate a greater burden of coronary
atherosclerosis compared with non-risk carriers. Al-
though studies with computerized tomography have
demonstrated a correlation between 9p21 and greater
coronary artery calcification, indicating a role in predis-
posing to atheroma formation (10,11), studies using
invasive coronary angiography as a more direct and
widely available means of visualizing plaque have dem-
onstrated discrepant results, leading to ongoing uncer-
tainty with regard to the mechanism of risk (12–15).
To address this lack of consistency we sought to establish
a collaboration of genetic studies and perform a compre-
hensive meta-analysis of the association between 9p21 and
angiographically defined CAD burden as well as to replicate
the lack of association with superimposed MI in subjects
with underlying CAD.
Methods
Search strategy and selection criteria. We performed a
systematic published data search for studies of 9p21 varia-
tion in relation to CAD/MI, published before June 2011 on
MEDLINE and EMBASE, combined with cross refer-
ences and manual searches. Search terms included “coronary
artery disease,” “myocardial infarction,” or “atherosclerosis,”
in combination with “9p21.” No language restrictions were
used. A hand-search of articles and cited reference search
were also performed to identify all articles that cited the
index publication. Experts contributed to identification of
cohorts with published and unpublished data (M.R./N.J.S.).
For each included cohort, data were tabulated for angio-
graphic presence or absence of CAD, burden of CAD,
number of MI cases in subjects with underlying CAD, and
the diabetic status of all subjects. Published data search,
data collection/abstraction, and entry were performed
independently and reconciled by 2 trained investigators
(K.C. and R.P.).
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March 5, 2013:957–70 9p21 and Angiographic CADFor the analysis of 9p21 association with atherosclerosis
burden, only studies with coronary angiographic data in
relation to 9p21 single nucleotide polymorphisms (SNPs)
were included. For the analysis of 9p21 association with MI
in subjects with underlying CAD, studies were included if
they had information for both CAD status (angiographic or
clinical diagnosis) and MI sufficient to classify individuals as
MI/CAD or MI/CAD. Myocardial infarction was
efined with standard criteria on the basis of clinical
ymptoms, electrocardiography, and raised troponin (16).
oronary artery disease was defined as angiographically
ocumented CAD (50% or 70% luminal stenosis on
isual estimation) or clinical CAD on the basis of physician
iagnosis with history of prior coronary revascularization.
tudies that used only the single phenotypes of CAD or MI
r an indistinguishable admixture of phenotypes in primary
omparisons with healthy control populations were not
ncluded.
ata sources. We contacted the principal investigators
f the identified studies/cohorts meeting inclusion crite-
ia to obtain complete published and unpublished data
or the prevalence of MI in subjects with CAD as well as
ngiographic data where available. For 2 of the eligible
tudies, sufficient data were unavailable in the published
Study
Study A. Presence or absence of angiographic CAD
(n=13,150; 6 cohorts)
Study B. Studies with angiographic data and
included in meta-analysis of atherosclerosis
burden (n=20,987; 13 cohorts)
Study C. Studies included in CAD/MI+ versus
CAD/MI- meta-analysis (n=33,673; 29 cohorts)
Potenally relevant citaons idenﬁed and
screened from MEDLINE and EMBASE through
June 2011 (n = 114). Cohorts and citaons fou
through search of reference lists (n=2)
Studies reviewed in full (n =27), 2 had suﬃcie
published data for the analyses.
Principle invesgators contacted for data (n =
Data abstracted from publicaons (n=2)
21 studies (29 unique cohorts) included in th
analysis
Figure 1 Published Data Search Results Identifying Association
CAD  coronary artery disease; MI  myocardial infarction.eports and could not be ob-
ained on request (Online Ta-
le 1). Details of all included
tudy cohorts are provided in
he Online Appendix. From the
ndividual studies, we received
or abstracted) information
bout: 1) angiographic CAD,
pecifically on the number of
iseased major epicardial ves-
els and criteria used to define
isease (50% or 70% lumi-
al stenosis on visual estima-
ion); and 2) prevalence of MI
n the presence or absence of
AD by 9p21 genotype. We
lso collected details on race,
ex, age, diabetes status (docu-
ented history of diabetes), and the identification (rs
umber) of the particular SNP genotyped.
tatistical analysis. Statistical analysis followed guidelines
rom the Cochrane Handbook for Systematic Reviews and
uGE Review Handbook for meta-analysis of genetic
ssociation studies (17,18). Random effect models (DerSi-
Control
8 angiographic CAD 2,722 angiographic
controls
2 mul-vessel
se CAD
6,755 single-vessel
disease CAD
1 CAD+/MI+ 15,882 CAD+/MI-
Excluded because arcle types were
reviews or leers, or repeated
studies on the same cohort (n=89)
Excluded because studies only
measured myocardial infarcon or
coronary artery disease against
healthy populaons (n=4)
Data not obtainable (n=2)
dies for 9p21 and CAD/MI
Abbreviations
and Acronyms
CAD  coronary artery
disease
CHD  coronary heart
disease
CI  confidence interval
GWAS  genome-wide
association studies
LD  linkage disequilibrium
MI  myocardial infarction
OR  odds ratio
SNP  single nucleotide
polymorphism
VSMC  vascular smooth
muscle cellCase
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Description of Studies Included in Meta-AnalysisTable 1 Description of Studies Included in Meta-Analysis
First Author (Ref. #) Cohort Country
SNP (effect
allele)
Risk Allele
Frequency Mean or Cutoff Age (yrs) Ethnicity Male%
Coronary Angiography No. of Subjects CAD Definitions
1-Vessel
Disease
2-Vessel
Disease
3-Vessel
Disease
CAD/MI
(nondiabetic
subjects)
CAD/MI
(nondiabetic
subjects) CAD Definition
Assimes et al. (11) ADVANCE U.S. rs10757278 (G) 0.53 Mean age 58.2. Early
onset CAD were 18 to
45 yrs (men) and 18 to
55 women, older onset
were any age 18 but
also not eligible to be
included in early onset
group
European ancestry/
African/East
Asian/South
Asian
67.7% — — — 1,005 (809) 547 (432) Clinical/
symptomatic
Broadbent et al.
(23)*
PROCARDIS Germany,
Italy,
Sweden,
and U.K.
rs1333049 (C) 0.52 Mean age (at date of
recruitment) 62.2 yrs
European ancestry 72.7% — — — 2,890 (2449) 1361 (1158) Clinical/
symptomatic
Chen et al. (15) LCAS U.S. rs1333049 (C) 0.55 Mean age 59.37.7, all
75 yrs
European ancestry 84.0% — — — 141 191 Angiography
(30%–75%
stenosis)
Dandona et al. (12) OHGS (Early
onset)
U.S. rs1333049 (C) 0.55 Mean age 56.19.6,
male 55 yrs and
female 65 yrs
European ancestry 70.8% 518 563 633 517 (517) 433 (433) Angiography
(50%
stenosis)
OHGS (Late
onset)
U.S. rs1333049 (C) 0.55 Mean age 70.08.0 European ancestry 82.6% — — — 271 (271) 493 (493) Angiography
(50%
stenosis)
Ellis et al. (9) CDCS New Zealand rs1333049 (C) 0.51 Mean age 67.112.5 European ancestry/
Asian/ Pacific
Island ancestry
69.2% 201 205 272 854 (703) 162 (142) Angiography
(50%
stenosis)
Gong et al. (25) INVEST U.S. rs1333049 (C) 0.54 Mean age 6610 European ancestry/
African/Hispanic
44.2% — — — 443 (344) 997 (713) Clinical/
symptomatic
Hauser et al. CATHGEN U.S. rs10757278 (G) 0.52 Mean age 64.411.0
(CAD/MI group),
61.0210.65 (CAD/
MI group)
European ancestry 73.0% 1,049 792 1180 1,357 (941) 1664 (1,159) Angiography
(50%
stenosis)
Hazen et al. Cleveland
GB
USA rs1333049 (C) 0.54 Mean age 61.7.911.1 European ancestry 74.0% 745 672 1,054 1,332 (1039) 1079 (806) Angiography
(50%
stenosis)
Hinohara et al. (36) — Japan rs1333049 (C) 0.56 Mean age 59.310.1 Japanese 83.3% 245 170 181 572 (395) 47 (29) Angiography
(50%
stenosis)
Hinohara et al. (36) — Korea rs1333049 (C) 0.52 Mean age 61.211.1 Korean 76.4% 243 162 117 433 (222) 260 (51) Angiography
(50%
stenosis)
Hoppmann et al. (37) — Germany rs1333049 (C) 0.51 Mean age 66.310.5 European ancestry 78.2% 364 579 1,085 733 1295 Angiography
(50%
stenosis)
Continued on the next page
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ContinuedTable 1 Continued
First Author (Ref. #) Cohort Country
SNP (effect
allele)
Risk Allele
Frequency Mean or Cutoff Age (yrs) Ethnicity Male%
Coronary Angiography No. of Subjects CAD Definitions
1-Vessel
Disease
2-Vessel
Disease
3-Vessel
Disease
CAD/MI
(nondiabetic
subjects)
CAD/MI
(nondiabetic
subjects) CAD Definition
Horne et al. (7) IHCS (Sample
set)
U.S. rs2383206 (C) 0.54 Mean age 6310 yrs
(range 21–78 yrs),
European
ancestry
77.0% 666 473 609 869 (613) 879 (705) Angiography
(70%
stenosis)
IHCS
(Replication
set)
U.S. rs2383206 (C) 0.53 Mean age 6110 yrs
(range 24–75 yrs),
European
ancestry
73.0% 429 300 285 507 (347) 507 (368) Angiography
(70%
stenosis)
Krawczak et al. (38) PopGen Germany rs1333049 (C) 0.51 Mean age 47.66.3 European
ancestry
79.4% — — — 1,366 (1,111) 718 (584) Angiography
(70%
stenosis)
Muendlein et al. (39) — Austria rs1333049 (C) 0.55 Mean age 65.1 10.6;
male 64.1 10.8;
female 68.6 9.2
European
ancestry
77.1% 362 290 262 357 (248) 576 (429) Angiography
(50%
stenosis)
Patel et al. (13) EmCB U.S. rs10757278 (G) 0.51 Mean age 63.911 European
ancestry
67.8% 498 545 1,314 891 (611) 864 (596) Angiography
(50%
stenosis)
Reilly et al. (8) MEDSTAR U.S. rs1333049 (C) 0.54 All aged 61, male 55
and female 60
European
ancestry
71.9% 330 290 204 421 (294) 454 (308) Angiography
(50%
stenosis)
Reilly et al. (8) PENNCATH U.S. rs1333049 (C) 0.57 All aged 66, male 60
and female 65
European
ancestry
75.0% 247 258 336 470 (123) 463 (111) Angiography
(50%
stenosis)
Samani et al. (1) WTCCC U.K. rs1333049 (C) 0.55 All Aged 66 European
ancestry
79.5% — — — 1,376 (1214) 532 (467) Clinical/
symptomatic
Shen et al. (40) SK-CAD Korea rs10757278 (G) 0.53 Mean age 63.710.1 Korean 70.9% — — — 603 (410) 485 (332) Angiography
(70%
stenosis)
Wang et al. (41) — China rs1333049 (C) 0.54 Mean age 66.819.8 Chinese 56.1% 419 389 357 555 (300) 610 (245) Angiography
(50%
stenosis)
Ye et al. (42) SAS U.K. rs1333049 (C) 0.52 Mean age 63.29.95 European
ancestry
76.6% 439 373 282 592 (513) 501 (434) Angiography
(50%
stenosis)
*Allele frequencies were estimated from computed odds ratio.
CDCS Coronary Disease Cohort Study; Cleveland GB Cleveland GeneBank Study; EmCB Emory Cardiovascular Biobank; IHCS Utah Intermountain Heart Collaborative Study; LCAS Lipoprotein and Coronary Atherosclerosis Study; INVEST International Verapamil
SR Trandolapril Study Genetic Substudy; OHGS  Ottawa Heart Genomics Study; PROCARDIS  Precocious Coronary Artery Disease; SAS  Southampton Atherosclerosis Study; WTCCC  Wellcome Trust Case-Control Consortium.
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9p21 and Angiographic CAD March 5, 2013:957–70monian and Laird) were used to estimate the pooled
per-allele and per-genotype odds ratios (ORs) and 95%
confidence intervals (CIs) according to the 9p21 polymor-
phism genotypes (RR, homozygous risk allele carrier; RW,
heterozygous risk allele carrier; WW, homozygous reference
group) with results presented as Forest plots (19).
Meta-analysis was first performed for association between
9p21 and angiographic CAD against angiographic control
subjects with the cohorts that had data available for both.
Angiographic control subjects were defined as having com-
pletely smooth unobstructed vessels or 10% luminal ste-
nosis anywhere in the coronary tree. Subsequently we
examined association with angiographic CAD burden, by
comparing subjects with coronary atherosclerosis/stenosis in
a single-vessel with those with 2-vessel, 3-vessel, or multi-
vessel (1 vessels) disease. Subgroup analyses were planned
a priori to investigate the association with multivessel
disease by study size, race, and diabetes status. Finally, we
estimated a pooled estimate for odds of prevalent MI in the
Figure 2 Association Between 9p21 and Multivessel CAD as C
(A) Odds ratio (OR)/copy of risk allele (allelic model). Continued on the next pagepresence of underlying CAD (all CAD definitions), by acomparing those with MI and CAD (MI/CAD) with
those without MI but with CAD (MI/CAD). For the
latter we also performed a priori subgroup analysis for
alternate classifications of CAD, including: 1) clinical
diagnosis alone; 2) 50% stenosis on coronary angiog-
raphy; or 3) 70% stenosis on coronary angiography.
In all meta-analyses we used Cochran’s Q test to evaluate
the degree of heterogeneity between studies and the I2
statistic to measure the proportion of total variation in study
estimates attribute to heterogeneity (20). This was further
investigated through subgroup analyses on the basis of
cohort size, ethnicity, and diabetic status of individual
patients. In addition to subgroup analyses by cohort size,
possible publication bias was also explored by analysis of a
funnel plot and Egger’s test (21). We identified a priori that
a major source of between-study heterogeneity is likely to
arise due to use of different 9p21 markers in different
studies. The markers used in this series of studies included
rs1333049 (C), rs10757278 (G), and rs2383206 (G), which
red With Single-Vessel CADompa
.re all in tight linkage disequilibrium (LD) (Online Fig. S1).
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March 5, 2013:957–70 9p21 and Angiographic CADTherefore, we used a random effects model to permit
heterogeneity in the association being measured between
studies. This delivers more conservative CIs than a fixed
effects model. However, to further model individual 9p21
SNP effects we also applied a Bayesian method, devel-
oped to address the problem of meta-analyzing gene-
disease association studies that report different SNPs.
Rather than including all SNPs in a single univariate test
under an assumption of exchangeability (as in the afore-
mentioned random effects analysis), separate effects are
modeled for each SNP as part of an adjusted multivariate
model. This is made possible by imputing the unobserved
SNPs in each study according to LD information from
HapMap. Further details are available in the Online
Appendix Methods section.
The random effects meta-analyses were performed with a
TATA software package (version 11.0, College Station,
exas). Bayesian analysis was performed with the Java
ackage “BayesMeta,” described in Newcombe et al. (22).
ost hoc power calculations were performed with G*power
Figure 2 Continued
(B) heterozygote risk versus homozygote non-risk (genotypic model), random-effecoftware package. Figures were created with STATA. lResults
Characteristics of the study cohorts. We identified 114
studies matching our database search terms, for association
between 9p21 and CAD and/or MI with a further 2
identified through manual searching of references. Of these,
89 were excluded, because they were reviews, letters, or
repeat studies on the same cohorts. A further 4 studies were
excluded, because they only examined associations between
CAD/MI with healthy control subjects. Of the remaining
23 studies, 2 had sufficient data published for this meta-
analysis. We contacted the PIs for the 21 other studies and
received information from 19. In total, sufficient data for
meta-analysis were obtained for 21 studies consisting of 29
unique cohorts (Fig. 1).
Of the 21 studies included, there were 6 cohorts (n 
3,150) available for study A (presence/absence angio-
raphic CAD), 13 cohorts (n 20,987) for study B (burden
f angiographic CAD), and 29 cohorts (n  33,673) for
tudy C (prevalent MI in CAD subjects) (Fig. 1). Table 1
lysis;ts anaists age, sex, and ethnicity distributions of the different
6
1
h
d
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9p21 and Angiographic CAD March 5, 2013:957–70cohorts. The mean age for the populations ranged from 47.6
to 70.0 years; 73.1% were male, with 86.1% of European
ancestry, 11.1% Asians, 1.5% Hispanics, and 0.9% Africans;
52.8% of the pooled population had a history of MI (Table 1).
Genotype frequency data were obtained for all studies
except 1, for which only summary statistics were available
(23). The genotype distributions for all 9p21 markers
were in agreement with Hardy-Weinberg equilibrium,
with overall risk allele frequencies similar to HapMap
and published reports.
Study A: 9p21 association with angiographic CAD presence/
absence. We first confirmed an association between the
9p21 risk locus and presence or absence of angiographic
CAD, with a subset of studies in which genotype data were
also available for those with normal coronary arteries on
angiography (n 10,428 cases, n 2,722 control subjects).
Figure 2 Continued
(C) homozygote risk versus homozygotes non-risk (genotypic model), random-e
vessel disease. Non-European ancestry cohorts were not included in the Bayes
rs10757278/rs1333049 and rs2383206, for which the marginal effect estima
CDCS  Coronary Disease Cohort Study; Cleveland GB  Cleveland GeneBank
Cardiovascular Biobank; IHCS  Utah Intermountain Heart Collaborative Study;
Study.Meta-analysis revealed an overall pooled allelic OR of 1.31 n(95% CI: 1.20 to 1.43) for association with angiographic
CAD (Online Fig. S2A). Heterozygotes for the risk allele
had 39% greater odds of having CAD (OR: 1.39, 95%
CI: 1.21 to 1.59), compared with those without any risk
alleles, whereas homozygotes for the risk allele had 73%
greater odds (OR: 1.73, 95% CI: 1.45 to 2.05) (Online
Figs. S2B and S2C).
Study B: 9p21 association with atherosclerosis burden on
angiographic CAD. In the combined analysis on all those
with angiographic CAD (n 20,987), the 9p21 risk variant
was associated with a greater odds of multivessel disease
(n  14,232) compared with single-vessel disease (n 
755), with a summary OR of 1.10 (95% CI: 1.04 to
.17)/risk allele (Fig. 2A). Under genotypic models,
eterozygotes had 15% greater odds of having multivessel
isease (OR: 1.15, 95% CI 1.04 to 1.26), compared with
analysis. Total n  20,987; 14,232 multivessel disease, 6,755 single-
alysis. Bayesian analysis showed no distinguishable differences between
s nearly identical. CI  confidence interval; Bayesian  Bayesian model;
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1.39) (Figs. 2B and 2C). The 9p21 risk allele carriers also
howed significantly increased odds of 2-vessel disease over
-vessel disease (OR: 1.08, 95% CI: 1.02 to 1.13) as well as
-vessel disease over 2-vessel disease (OR: 1.07, 95% CI:
.01 to 1.13) (Online Figs. S3 and S4).
There was some evidence of heterogeneity between stud-
es (I2  49.5%, Q  27.7, p  0.015, Egger test p 
.058). However, upon exclusion of smaller studies (n 
,000), the evidence of heterogeneity substantially reduced
I2 43.2%, Q  14.1, p  0.08, Egger test p  0.69),
uggesting that part of the heterogeneity was caused by
ublication bias. The funnel plot across all studies was also
Figure 3 Summary ORs/Copy of 9p21 Risk Allele for Multivess
Categorized by subgroups of study size, ethnicity, and diabetes status. CI  confionsistent with possible publication bias (Online Fig. S8). tncouragingly, the effect estimate was robust to exclusion of
he smaller (n  1,000) studies: Among the 9 remaining
tudies (total sample size of n  16,612) the meta-analyzed
R was 1.15 (95% CI: 1.08 to 1.23).
Although studies of subjects of European ancestry and
tudies of Asians showed similar effect sizes, the association
as nonsignificant for the studies of Asians, likely due to
maller overall sample size (OR: 1.12, 95% CI 0.92 to 1.35,
 2,283). Diabetes status did not significantly alter the
ssociation of 9p21 with greater CAD burden (Fig. 3).
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of LD observed in HapMap (r2 1 for rs1333049 and
s10757278; and r2 0.87 for rs1333049 and rs2383206).
Study C: No association between 9p21 and MI in
subjects with CAD. The 9p21 SNPs did not show a
significant association with MI when comparing MI cases
with control subjects consisting of subjects without MI but
with underlying CAD (Fig. 4). The summary effect size was
estimated at 0.99 (95% CI: 0.95 to 1.03)/risk allele, with no
evidence of publication bias (Egger p  0.843) and little
heterogeneity between studies (I2  20.9%) (Online Fig. S9).
imilar findings were noted in genotypic analysis, with an
Figure 4 Association Between 9p21 and MI in Patients With U
Odds ratios/copy of 9p21 risk allele for MI in subjects with CAD (allelic model), st
Total n  33,673; 17,791 CAD/MI, 15,882 CAD/MI. ADVANCE  Atheros
history of MI and underlying CAD; CAD/MI  control subjects without history of M
PROCARDIS  Precocious Coronary Artery Disease; WTCCC  Wellcome Trust CasR of 0.98 (95% CI: 0.92 to 1.04) for heterozygotes and c.99 (95% CI: 0.91 to 1.07) for homozygotes (Online Figs.
5 and S6). Subgroup analysis revealed that the findings
ere not significantly altered by CAD definition (on the
asis of clinical definitions or confirmed angiographic ste-
osis of50% or70%), ethnicity, study size, and diabetes
tatus of the population (Online Fig. S7). Results from the
ayesian meta-analysis were entirely consistent with those
escribed in the preceding text (Online Table 2).
iscussion
e have demonstrated, through a comprehensive and
ying CAD
according to CAD definition (clinical, angiographic stenosis 50% or 70%).
c Disease, Vascular Function, and Genetic Epidemiology; CAD/MI  cases with
with underlying CAD; LCAS  Lipoprotein and Coronary Atherosclerosis Study;
trol Consortium; other abbreviations as in Figures 1, 2, and 3.nderl
ratified
cleroti
I but
e-Conollaborative meta-analysis, that the 9p21 risk locus is
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CAD. Homozygotes for the risk allele are 23% more likely
to have multivessel disease than single-vessel disease when
compared with homozygotes for the non-risk allele. Fur-
thermore, we confirmed that there is no association between
9p21 and MI in the presence of background CAD. These
results support the hypothesis that the 9p21 locus primarily
promotes atherosclerotic lesion development and function-
ally significant coronary stenosis rather than precipitating
plaque rupture and thrombosis.
Early GWAS demonstrated significant association be-
tween 9p21 and both MI and CAD (1–3). Given that MI
predominantly occurs in those with CAD, it was initially
unclear whether 9p21 promoted the upstream phenotype of
atherosclerosis or the later complication of MI. Subsequent
studies attempted to refine this phenotype and demon-
strated robust association with CAD, including angio-
graphically defined atherosclerosis (7). Three large studies
have demonstrated further association between 9p21 and
CAD burden with a number of diseased vessels or semi-
quantitative methods such as the Gensini score, suggesting
that 9p21 promotes progressive atherosclerosis (12,13,24).
However, other studies have not confirmed this association,
and this lack of consistency has led to difficulties in
reconciling association with presence but not extent of
CAD (14,15). However, this meta-analysis, which includes
almost all published and unpublished reports on 9p21 and
angiographic CAD, convincingly demonstrates that 9p21 is
associated with greater CAD burden, overall.
Interestingly, subgroup analysis showed that study size
significantly influenced the observed effect. Association with
multivessel disease was observed in large studies (sample size
1,000) with similar effect size as the overall pooled results
but not in smaller studies. Several of the smaller studies
reported on association with CAD burden as secondary
analysis, not suitably powered to detect differences in a
crude phenotype (number of vessels with significant steno-
ses) combined with a modest genetic effect. Ethnicity
meanwhile did not seem to influence the overall association,
although the smaller Asian population size rendered a wide
CI. Finally, diabetes status showed little modification on the
results, which is relevant given the exclusion of diabetic
cases in some of the reported studies (12).
Additionally, we demonstrated in a sample size of 33,673
that the 9p21 locus was not associated with prevalent MI
when both cases and control subjects had documented
CAD. This analysis has been proposed by others as a means
to tease out the effect of 9p21 on CAD and MI. Given that
MI primarily occurs in the presence of CAD, comparing
MI cases with healthy control subjects might also be testing
the hypothesis of CAD versus no CAD. Thus, by examin-
ing control subjects without MI but with underlying CAD,
one can determine whether 9p21 truly associates with an MI
phenotype, such as tendency to plaque instability or throm-
bosis, or not (7,8,14,25). However, if the locus promotes
atherosclerosis, then no association would be observed,because the frequency of risk allele would be similar in both
cases and control subjects. In the largest such analysis to
date, Reilly et al. (8) demonstrated in 9,427 subjects that
9p21 along with other novel genomic variants did not reach
statistically significant associations with MI when all sub-
jects had angiographic CAD. Our analysis adds to these
findings by including almost 4 times as many subjects.
Furthermore, we also ascertained that the various defini-
tions of CAD do not influence this observation, and neither
does race, diabetes, or study size.
Therefore, our results support the hypothesis that the
9p21 risk locus primarily promotes an atherosclerotic pro-
cess and is not associated with a thrombotic or plaque
rupture phenotype. These findings are consistent with
several lines of evidence, including significant associations
with: 1) subclinical atherosclerosis (26); 2) coronary calcifi-
cation (10,11); 3) carotid atherosclerosis (27); and 4) pe-
ripheral arterial disease (28,29). Additionally, these data are
also in line with the observations that 9p21 variants are
associated with earlier age of CAD onset as well as emerg-
ing evidence that 9p21 does not predict risk of incident MI
events in those with existing CAD (9,25,30).
Biological studies have also yielded important data sug-
gesting an atherogenic mechanism. The nearest genes to the
non-coding 9p21 region include cyclin-dependent kinase
inhibitors associated with cell cycling and death, which are
relevant to the atherosclerotic process (31). Visel et al. (32)
observed, in a mouse knockout model for the orthologous
9p21 region, increased expression of these cyclin-dependent
kinase inhibitors (CDKN2A and CDKN2B), with excessive
proliferation and diminished senescence of vascular smooth
muscle cells (VSMCs). More recently, Kim et al. (33)
reported that CDKN2A knockout mice demonstrate
smaller aortic atheromatous lesions compared with wild-
type mice. Furthermore, the 9p21 variant has been shown to
be associated with CDKN2A and CDKN2B expression in
VSMCs, VSMC proliferation, and VSMC content in
atherosclerotic plaque (34), whereas proliferation of neoin-
timal content of macrophages has also been described (35).
These are all key pathological changes implicated in the
early development and progression of atherosclerotic
plaques. The exact mechanistic pathway leading to these
events remains to be elucidated, although the regulatory role
of the 9p21 region is likely to involve antisense non-coding
ribonucleic acid (ANRIL) at a transcription level (34) and
extensive compensatory regulation of gene expression (33).
Thus, our finding of enhanced atherosclerosis in humans
provides robust proof of concept for emerging mechanistic
and murine studies demonstrating a possible proliferative
phenotype for the 9p21 risk locus.
Implications. By refining the underlying phenotype, this
study has significant implications for our understanding of
the 9p21 risk locus. Firstly, by demonstrating that the
mechanism of risk is likely through development of athero-
sclerosis, our work helps translate and contextualize func-
tional studies, which in turn has potential implications for
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and cardiovascular risk. Secondly, these findings might help
explain why 9p21 does not enhance risk prediction for MI,
given that this is a more downstream phenotype. With
expanding use of direct-to-consumer and physician-ordered
testing for 9p21, this work will have greater relevance and
will better inform those interpreting these tests about the
actual underlying genetic risk.
Strengths and limitations. The major strength of this
study is the collaborative collection of cohorts combining
published and unpublished data, including 14 that had not
previously reported on data with regard to presence of MI in
subjects with CAD. We also present the use of a Bayesian
analysis to account for potential heterogeneity from use of
different 9p21 markers and confirm from a statistical per-
spective that the several 9p21 markers (rs1333049,
rs10757278, and rs2383206) can be used interchangeably in
meta-analyses such as this. There are also some limitations
to our study. First, the cohorts with angiographic data are
inherently subject to selection bias, but because our primary
objective was to determine differences in disease burden,
this is not a major concern. Second, we noted significant
heterogeneity between the studies, and although it is pos-
sible that there were some clinical differences between
studies, such as referral bias in different countries, these are
likely to be small, and we devised a priori subgroup analyses
to investigate these further. Third, our phenotype was
relatively crude for assessing CAD burden, and we did not
have more details on, for example, presence of more
proximal prognostic disease, but this was unavoidable given
that few cohorts collect extensive CAD scores such as the
SYNTAX score (13). Finally, it is possible that we might
have missed a small effect of risk of MI in the context of
CAD, but post hoc power calculations suggested the anal-
ysis had 0.95 power to detect an OR of 1.1 for MI among
subjects with CAD. This observation combined with the
consistency of the data from different groups makes it
unlikely that the finding is spurious.
Conclusions
Our analysis reveals that the 9p21 risk locus is associated
with greater CAD burden but not with prevalent MI
when both cases and control subjects have documented
angiographic CAD. Taken together our meta-analysis
confirms that the primary phenotype mediated by the
9p21 locus is one of predisposition to greater atheroscle-
rosis.
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